The CXCR4 antagonist 4F-benzoyl-TN14003 stimulates the recovery of the bone marrow after transplantation
Cytopenia represents a significant complication after chemotherapy, irradiation before bone marrow (BM) transplantation or as a therapy for cancer. The mechanisms that determine the pace of BM recovery are not fully understood. During the recovery phase after chemotherapy or irradiation, the signals...
Gespeichert in:
| Veröffentlicht in: | Leukemia 2009-08, Vol.23 (8), p.1378-1388 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1388 |
|---|---|
| container_issue | 8 |
| container_start_page | 1378 |
| container_title | Leukemia |
| container_volume | 23 |
| creator | Abraham, M Beider, K Wald, H Weiss, I D Zipori, D Galun, E Nagler, A Eizenberg, O Peled, A |
| description | Cytopenia represents a significant complication after chemotherapy, irradiation before bone marrow (BM) transplantation or as a therapy for cancer. The mechanisms that determine the pace of BM recovery are not fully understood. During the recovery phase after chemotherapy or irradiation, the signals for retention of white blood cells within the BM increase significantly. This leads to a delay in the release of WBC, which can be overcome by targeting the CXCR4 axis with the antagonist 4F-benzoyl-TN14003 (T140). The delay in the release of WBC is also accompanied by suppression in the production of progenitor cells and mature cells by the BM stroma. Administration of T140 to mice transplanted with BM cells stimulates the production of all types of progenitors and mature cells, and increases the exit of mature cells to the periphery. Moreover, addition of T140, but not AMD3100, to BM stromal cultures stimulates the production of mature cells and progenitors from all lineages. The unique ability of the CXCR4 antagonist, T140 to stimulate the production and exit of WBC cells may be used as a novel therapeutic approach to overcome cytopenia associated with treatments for cancer and BM transplantation. |
| doi_str_mv | 10.1038/leu.2009.56 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_21145746</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A206599795</galeid><sourcerecordid>A206599795</sourcerecordid><originalsourceid>FETCH-LOGICAL-c665t-2fb4887f9026b35d80a68fa082a3ff0a47aa7f1347377e0f2704f51ea51f6c1e3</originalsourceid><addsrcrecordid>eNp10t1v0zAQAPAIgVg3eOIdIib2Ainn7-RxqhggTSChIvFmOem5zZTExXZA5a_HodXK0FAeosQ_n-_Ol2XPCMwJsPJth-OcAlRzIR9kM8KVLIQQ5GE2g7JUhawoP8lOQ7gBmBbl4-yEVIxSCmqWbZYbzBffFl94boZo1m5oQ8z5VVHj8MvtumL5iXAAlofY9mNnIoY8pi0eG_cD_S539s937QbMe-O9-5kbG9Hn0ZshbLspamzd8CR7ZE0X8OnhfZZ9vXq3XHworj-__7i4vC4aKUUsqK15ytpWQGXNxKoEI0troKSGWQuGK2OUJYwrphSCpQq4FQSNIFY2BNlZdrGPu_Xu-4gh6r4NDXYpEXRj0JQQLhSXCZ7_A2_c6IeUm6ZyIlACSerlfxUFwUBSegy1Nh3qdrAuFd9M5-pLClJUlapEUvN7VHpW2LdN6p9t0_87Gy7-2rBB08VNcN04tTPcha_3sPEuBI9Wb32bLmOnCehpRnSaET3NiBZT4c8PJY11j6ujPQxFAq8OwITGdDZdZNOGW0dJyYBIltybvQtpaVijP_bm_nNf7Plg4ujxNl4yE0niN9eL2Oc</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>220530622</pqid></control><display><type>article</type><title>The CXCR4 antagonist 4F-benzoyl-TN14003 stimulates the recovery of the bone marrow after transplantation</title><source>MEDLINE</source><source>Nature</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><creator>Abraham, M ; Beider, K ; Wald, H ; Weiss, I D ; Zipori, D ; Galun, E ; Nagler, A ; Eizenberg, O ; Peled, A</creator><creatorcontrib>Abraham, M ; Beider, K ; Wald, H ; Weiss, I D ; Zipori, D ; Galun, E ; Nagler, A ; Eizenberg, O ; Peled, A</creatorcontrib><description>Cytopenia represents a significant complication after chemotherapy, irradiation before bone marrow (BM) transplantation or as a therapy for cancer. The mechanisms that determine the pace of BM recovery are not fully understood. During the recovery phase after chemotherapy or irradiation, the signals for retention of white blood cells within the BM increase significantly. This leads to a delay in the release of WBC, which can be overcome by targeting the CXCR4 axis with the antagonist 4F-benzoyl-TN14003 (T140). The delay in the release of WBC is also accompanied by suppression in the production of progenitor cells and mature cells by the BM stroma. Administration of T140 to mice transplanted with BM cells stimulates the production of all types of progenitors and mature cells, and increases the exit of mature cells to the periphery. Moreover, addition of T140, but not AMD3100, to BM stromal cultures stimulates the production of mature cells and progenitors from all lineages. The unique ability of the CXCR4 antagonist, T140 to stimulate the production and exit of WBC cells may be used as a novel therapeutic approach to overcome cytopenia associated with treatments for cancer and BM transplantation.</description><identifier>ISSN: 0887-6924</identifier><identifier>EISSN: 1476-5551</identifier><identifier>DOI: 10.1038/leu.2009.56</identifier><identifier>PMID: 19322207</identifier><identifier>CODEN: LEUKED</identifier><language>eng</language><publisher>London: Nature Publishing Group UK</publisher><subject>Animals ; Biological and medical sciences ; Bone marrow ; Bone Marrow - drug effects ; Bone Marrow - radiation effects ; Bone marrow transplantation ; Cancer ; Cancer Research ; Care and treatment ; Cell Division - drug effects ; Cell proliferation ; Chemotherapy ; Coculture Techniques ; Colony-Forming Units Assay ; Critical Care Medicine ; CXCR4 protein ; Cyclophosphamide - pharmacology ; Cytopenia ; Drug Evaluation, Preclinical ; Female ; Graft Survival - drug effects ; Hematologic and hematopoietic diseases ; Hematology ; Hematopoiesis ; Hematopoietic Stem Cell Mobilization - methods ; Hematopoietic Stem Cells - cytology ; Hematopoietic Stem Cells - drug effects ; Hematopoietic Stem Cells - metabolism ; Heterocyclic Compounds - pharmacology ; Heterocyclic Compounds - therapeutic use ; Integrin alpha4beta1 - biosynthesis ; Intensive ; Internal Medicine ; Irradiation ; Leukemia ; Leukocytes ; Matrix Metalloproteinase 9 - metabolism ; Medical sciences ; Medicine ; Medicine & Public Health ; Mice ; Mice, Inbred C57BL ; Neutropenia - drug therapy ; Neutropenia - etiology ; Oncology ; original-article ; Peptides - pharmacology ; Peptides - therapeutic use ; Physiological aspects ; Progenitor cells ; Radiation ; Radiation Chimera ; Receptors, CXCR4 - antagonists & inhibitors ; Receptors, CXCR4 - biosynthesis ; Receptors, CXCR4 - physiology ; Recovery ; Recovery (Medical) ; Recovery of Function - drug effects ; Specific Pathogen-Free Organisms ; Stem cells ; Stroma ; Stromal Cells - physiology ; Transplantation</subject><ispartof>Leukemia, 2009-08, Vol.23 (8), p.1378-1388</ispartof><rights>Macmillan Publishers Limited 2009</rights><rights>2009 INIST-CNRS</rights><rights>COPYRIGHT 2009 Nature Publishing Group</rights><rights>Copyright Nature Publishing Group Aug 2009</rights><rights>Macmillan Publishers Limited 2009.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c665t-2fb4887f9026b35d80a68fa082a3ff0a47aa7f1347377e0f2704f51ea51f6c1e3</citedby><cites>FETCH-LOGICAL-c665t-2fb4887f9026b35d80a68fa082a3ff0a47aa7f1347377e0f2704f51ea51f6c1e3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,2727,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=21830163$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/19322207$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Abraham, M</creatorcontrib><creatorcontrib>Beider, K</creatorcontrib><creatorcontrib>Wald, H</creatorcontrib><creatorcontrib>Weiss, I D</creatorcontrib><creatorcontrib>Zipori, D</creatorcontrib><creatorcontrib>Galun, E</creatorcontrib><creatorcontrib>Nagler, A</creatorcontrib><creatorcontrib>Eizenberg, O</creatorcontrib><creatorcontrib>Peled, A</creatorcontrib><title>The CXCR4 antagonist 4F-benzoyl-TN14003 stimulates the recovery of the bone marrow after transplantation</title><title>Leukemia</title><addtitle>Leukemia</addtitle><addtitle>Leukemia</addtitle><description>Cytopenia represents a significant complication after chemotherapy, irradiation before bone marrow (BM) transplantation or as a therapy for cancer. The mechanisms that determine the pace of BM recovery are not fully understood. During the recovery phase after chemotherapy or irradiation, the signals for retention of white blood cells within the BM increase significantly. This leads to a delay in the release of WBC, which can be overcome by targeting the CXCR4 axis with the antagonist 4F-benzoyl-TN14003 (T140). The delay in the release of WBC is also accompanied by suppression in the production of progenitor cells and mature cells by the BM stroma. Administration of T140 to mice transplanted with BM cells stimulates the production of all types of progenitors and mature cells, and increases the exit of mature cells to the periphery. Moreover, addition of T140, but not AMD3100, to BM stromal cultures stimulates the production of mature cells and progenitors from all lineages. The unique ability of the CXCR4 antagonist, T140 to stimulate the production and exit of WBC cells may be used as a novel therapeutic approach to overcome cytopenia associated with treatments for cancer and BM transplantation.</description><subject>Animals</subject><subject>Biological and medical sciences</subject><subject>Bone marrow</subject><subject>Bone Marrow - drug effects</subject><subject>Bone Marrow - radiation effects</subject><subject>Bone marrow transplantation</subject><subject>Cancer</subject><subject>Cancer Research</subject><subject>Care and treatment</subject><subject>Cell Division - drug effects</subject><subject>Cell proliferation</subject><subject>Chemotherapy</subject><subject>Coculture Techniques</subject><subject>Colony-Forming Units Assay</subject><subject>Critical Care Medicine</subject><subject>CXCR4 protein</subject><subject>Cyclophosphamide - pharmacology</subject><subject>Cytopenia</subject><subject>Drug Evaluation, Preclinical</subject><subject>Female</subject><subject>Graft Survival - drug effects</subject><subject>Hematologic and hematopoietic diseases</subject><subject>Hematology</subject><subject>Hematopoiesis</subject><subject>Hematopoietic Stem Cell Mobilization - methods</subject><subject>Hematopoietic Stem Cells - cytology</subject><subject>Hematopoietic Stem Cells - drug effects</subject><subject>Hematopoietic Stem Cells - metabolism</subject><subject>Heterocyclic Compounds - pharmacology</subject><subject>Heterocyclic Compounds - therapeutic use</subject><subject>Integrin alpha4beta1 - biosynthesis</subject><subject>Intensive</subject><subject>Internal Medicine</subject><subject>Irradiation</subject><subject>Leukemia</subject><subject>Leukocytes</subject><subject>Matrix Metalloproteinase 9 - metabolism</subject><subject>Medical sciences</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Mice</subject><subject>Mice, Inbred C57BL</subject><subject>Neutropenia - drug therapy</subject><subject>Neutropenia - etiology</subject><subject>Oncology</subject><subject>original-article</subject><subject>Peptides - pharmacology</subject><subject>Peptides - therapeutic use</subject><subject>Physiological aspects</subject><subject>Progenitor cells</subject><subject>Radiation</subject><subject>Radiation Chimera</subject><subject>Receptors, CXCR4 - antagonists & inhibitors</subject><subject>Receptors, CXCR4 - biosynthesis</subject><subject>Receptors, CXCR4 - physiology</subject><subject>Recovery</subject><subject>Recovery (Medical)</subject><subject>Recovery of Function - drug effects</subject><subject>Specific Pathogen-Free Organisms</subject><subject>Stem cells</subject><subject>Stroma</subject><subject>Stromal Cells - physiology</subject><subject>Transplantation</subject><issn>0887-6924</issn><issn>1476-5551</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2009</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNp10t1v0zAQAPAIgVg3eOIdIib2Ainn7-RxqhggTSChIvFmOem5zZTExXZA5a_HodXK0FAeosQ_n-_Ol2XPCMwJsPJth-OcAlRzIR9kM8KVLIQQ5GE2g7JUhawoP8lOQ7gBmBbl4-yEVIxSCmqWbZYbzBffFl94boZo1m5oQ8z5VVHj8MvtumL5iXAAlofY9mNnIoY8pi0eG_cD_S539s937QbMe-O9-5kbG9Hn0ZshbLspamzd8CR7ZE0X8OnhfZZ9vXq3XHworj-__7i4vC4aKUUsqK15ytpWQGXNxKoEI0troKSGWQuGK2OUJYwrphSCpQq4FQSNIFY2BNlZdrGPu_Xu-4gh6r4NDXYpEXRj0JQQLhSXCZ7_A2_c6IeUm6ZyIlACSerlfxUFwUBSegy1Nh3qdrAuFd9M5-pLClJUlapEUvN7VHpW2LdN6p9t0_87Gy7-2rBB08VNcN04tTPcha_3sPEuBI9Wb32bLmOnCehpRnSaET3NiBZT4c8PJY11j6ujPQxFAq8OwITGdDZdZNOGW0dJyYBIltybvQtpaVijP_bm_nNf7Plg4ujxNl4yE0niN9eL2Oc</recordid><startdate>20090801</startdate><enddate>20090801</enddate><creator>Abraham, M</creator><creator>Beider, K</creator><creator>Wald, H</creator><creator>Weiss, I D</creator><creator>Zipori, D</creator><creator>Galun, E</creator><creator>Nagler, A</creator><creator>Eizenberg, O</creator><creator>Peled, A</creator><general>Nature Publishing Group UK</general><general>Nature Publishing Group</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QL</scope><scope>7RV</scope><scope>7T5</scope><scope>7T7</scope><scope>7TM</scope><scope>7TO</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FD</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB0</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7N</scope><scope>M7P</scope><scope>NAPCQ</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope></search><sort><creationdate>20090801</creationdate><title>The CXCR4 antagonist 4F-benzoyl-TN14003 stimulates the recovery of the bone marrow after transplantation</title><author>Abraham, M ; Beider, K ; Wald, H ; Weiss, I D ; Zipori, D ; Galun, E ; Nagler, A ; Eizenberg, O ; Peled, A</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c665t-2fb4887f9026b35d80a68fa082a3ff0a47aa7f1347377e0f2704f51ea51f6c1e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2009</creationdate><topic>Animals</topic><topic>Biological and medical sciences</topic><topic>Bone marrow</topic><topic>Bone Marrow - drug effects</topic><topic>Bone Marrow - radiation effects</topic><topic>Bone marrow transplantation</topic><topic>Cancer</topic><topic>Cancer Research</topic><topic>Care and treatment</topic><topic>Cell Division - drug effects</topic><topic>Cell proliferation</topic><topic>Chemotherapy</topic><topic>Coculture Techniques</topic><topic>Colony-Forming Units Assay</topic><topic>Critical Care Medicine</topic><topic>CXCR4 protein</topic><topic>Cyclophosphamide - pharmacology</topic><topic>Cytopenia</topic><topic>Drug Evaluation, Preclinical</topic><topic>Female</topic><topic>Graft Survival - drug effects</topic><topic>Hematologic and hematopoietic diseases</topic><topic>Hematology</topic><topic>Hematopoiesis</topic><topic>Hematopoietic Stem Cell Mobilization - methods</topic><topic>Hematopoietic Stem Cells - cytology</topic><topic>Hematopoietic Stem Cells - drug effects</topic><topic>Hematopoietic Stem Cells - metabolism</topic><topic>Heterocyclic Compounds - pharmacology</topic><topic>Heterocyclic Compounds - therapeutic use</topic><topic>Integrin alpha4beta1 - biosynthesis</topic><topic>Intensive</topic><topic>Internal Medicine</topic><topic>Irradiation</topic><topic>Leukemia</topic><topic>Leukocytes</topic><topic>Matrix Metalloproteinase 9 - metabolism</topic><topic>Medical sciences</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Mice</topic><topic>Mice, Inbred C57BL</topic><topic>Neutropenia - drug therapy</topic><topic>Neutropenia - etiology</topic><topic>Oncology</topic><topic>original-article</topic><topic>Peptides - pharmacology</topic><topic>Peptides - therapeutic use</topic><topic>Physiological aspects</topic><topic>Progenitor cells</topic><topic>Radiation</topic><topic>Radiation Chimera</topic><topic>Receptors, CXCR4 - antagonists & inhibitors</topic><topic>Receptors, CXCR4 - biosynthesis</topic><topic>Receptors, CXCR4 - physiology</topic><topic>Recovery</topic><topic>Recovery (Medical)</topic><topic>Recovery of Function - drug effects</topic><topic>Specific Pathogen-Free Organisms</topic><topic>Stem cells</topic><topic>Stroma</topic><topic>Stromal Cells - physiology</topic><topic>Transplantation</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Abraham, M</creatorcontrib><creatorcontrib>Beider, K</creatorcontrib><creatorcontrib>Wald, H</creatorcontrib><creatorcontrib>Weiss, I D</creatorcontrib><creatorcontrib>Zipori, D</creatorcontrib><creatorcontrib>Galun, E</creatorcontrib><creatorcontrib>Nagler, A</creatorcontrib><creatorcontrib>Eizenberg, O</creatorcontrib><creatorcontrib>Peled, A</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Proquest Nursing & Allied Health Source</collection><collection>Immunology Abstracts</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Nucleic Acids Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Nursing & Allied Health Premium</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><jtitle>Leukemia</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Abraham, M</au><au>Beider, K</au><au>Wald, H</au><au>Weiss, I D</au><au>Zipori, D</au><au>Galun, E</au><au>Nagler, A</au><au>Eizenberg, O</au><au>Peled, A</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The CXCR4 antagonist 4F-benzoyl-TN14003 stimulates the recovery of the bone marrow after transplantation</atitle><jtitle>Leukemia</jtitle><stitle>Leukemia</stitle><addtitle>Leukemia</addtitle><date>2009-08-01</date><risdate>2009</risdate><volume>23</volume><issue>8</issue><spage>1378</spage><epage>1388</epage><pages>1378-1388</pages><issn>0887-6924</issn><eissn>1476-5551</eissn><coden>LEUKED</coden><abstract>Cytopenia represents a significant complication after chemotherapy, irradiation before bone marrow (BM) transplantation or as a therapy for cancer. The mechanisms that determine the pace of BM recovery are not fully understood. During the recovery phase after chemotherapy or irradiation, the signals for retention of white blood cells within the BM increase significantly. This leads to a delay in the release of WBC, which can be overcome by targeting the CXCR4 axis with the antagonist 4F-benzoyl-TN14003 (T140). The delay in the release of WBC is also accompanied by suppression in the production of progenitor cells and mature cells by the BM stroma. Administration of T140 to mice transplanted with BM cells stimulates the production of all types of progenitors and mature cells, and increases the exit of mature cells to the periphery. Moreover, addition of T140, but not AMD3100, to BM stromal cultures stimulates the production of mature cells and progenitors from all lineages. The unique ability of the CXCR4 antagonist, T140 to stimulate the production and exit of WBC cells may be used as a novel therapeutic approach to overcome cytopenia associated with treatments for cancer and BM transplantation.</abstract><cop>London</cop><pub>Nature Publishing Group UK</pub><pmid>19322207</pmid><doi>10.1038/leu.2009.56</doi><tpages>11</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0887-6924 |
| ispartof | Leukemia, 2009-08, Vol.23 (8), p.1378-1388 |
| issn | 0887-6924 1476-5551 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_21145746 |
| source | MEDLINE; Nature; EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection |
| subjects | Animals Biological and medical sciences Bone marrow Bone Marrow - drug effects Bone Marrow - radiation effects Bone marrow transplantation Cancer Cancer Research Care and treatment Cell Division - drug effects Cell proliferation Chemotherapy Coculture Techniques Colony-Forming Units Assay Critical Care Medicine CXCR4 protein Cyclophosphamide - pharmacology Cytopenia Drug Evaluation, Preclinical Female Graft Survival - drug effects Hematologic and hematopoietic diseases Hematology Hematopoiesis Hematopoietic Stem Cell Mobilization - methods Hematopoietic Stem Cells - cytology Hematopoietic Stem Cells - drug effects Hematopoietic Stem Cells - metabolism Heterocyclic Compounds - pharmacology Heterocyclic Compounds - therapeutic use Integrin alpha4beta1 - biosynthesis Intensive Internal Medicine Irradiation Leukemia Leukocytes Matrix Metalloproteinase 9 - metabolism Medical sciences Medicine Medicine & Public Health Mice Mice, Inbred C57BL Neutropenia - drug therapy Neutropenia - etiology Oncology original-article Peptides - pharmacology Peptides - therapeutic use Physiological aspects Progenitor cells Radiation Radiation Chimera Receptors, CXCR4 - antagonists & inhibitors Receptors, CXCR4 - biosynthesis Receptors, CXCR4 - physiology Recovery Recovery (Medical) Recovery of Function - drug effects Specific Pathogen-Free Organisms Stem cells Stroma Stromal Cells - physiology Transplantation |
| title | The CXCR4 antagonist 4F-benzoyl-TN14003 stimulates the recovery of the bone marrow after transplantation |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-28T03%3A00%3A35IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20CXCR4%20antagonist%204F-benzoyl-TN14003%20stimulates%20the%20recovery%20of%20the%20bone%20marrow%20after%20transplantation&rft.jtitle=Leukemia&rft.au=Abraham,%20M&rft.date=2009-08-01&rft.volume=23&rft.issue=8&rft.spage=1378&rft.epage=1388&rft.pages=1378-1388&rft.issn=0887-6924&rft.eissn=1476-5551&rft.coden=LEUKED&rft_id=info:doi/10.1038/leu.2009.56&rft_dat=%3Cgale_proqu%3EA206599795%3C/gale_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=220530622&rft_id=info:pmid/19322207&rft_galeid=A206599795&rfr_iscdi=true |